Cargando…
Lung Cancer Surgery after Neoadjuvant Immunotherapy
SIMPLE SUMMARY: Neoadjuvant immunotherapy is a novel approach for lung cancer patients in stages where curative intent treatment is possible. The rationale is a based on the idea that recognition by the immune system is activated by the entire tumor prior to surgical resection. Promising pathologic...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8393473/ https://www.ncbi.nlm.nih.gov/pubmed/34439187 http://dx.doi.org/10.3390/cancers13164033 |
_version_ | 1783743734220849152 |
---|---|
author | Stefani, Dirk Plönes, Till Viehof, Jan Darwiche, Kaid Stuschke, Martin Schuler, Martin Aigner, Clemens |
author_facet | Stefani, Dirk Plönes, Till Viehof, Jan Darwiche, Kaid Stuschke, Martin Schuler, Martin Aigner, Clemens |
author_sort | Stefani, Dirk |
collection | PubMed |
description | SIMPLE SUMMARY: Neoadjuvant immunotherapy is a novel approach for lung cancer patients in stages where curative intent treatment is possible. The rationale is a based on the idea that recognition by the immune system is activated by the entire tumor prior to surgical resection. Promising pathologic response rates have been reported and the impact on survival is currently investigated in ongoing studies. ABSTRACT: In early-stage lung cancer, recurrences are observed even after curative resection. Neoadjuvant immunotherapy might be a promising approach to eliminate micrometastasis and to potentially reduce recurrence rates and improve survival. Early trials have shown encouraging rates of pathologic response to neoadjuvant therapy and have demonstrated that surgery can be safely performed after neoadjuvant immunotherapy with various agents and in combination with chemo-(radio)therapy. However, whether these response rates translate into improved disease-free survival rates and overall survival rates remains to be determined by ongoing phase III studies. |
format | Online Article Text |
id | pubmed-8393473 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-83934732021-08-28 Lung Cancer Surgery after Neoadjuvant Immunotherapy Stefani, Dirk Plönes, Till Viehof, Jan Darwiche, Kaid Stuschke, Martin Schuler, Martin Aigner, Clemens Cancers (Basel) Review SIMPLE SUMMARY: Neoadjuvant immunotherapy is a novel approach for lung cancer patients in stages where curative intent treatment is possible. The rationale is a based on the idea that recognition by the immune system is activated by the entire tumor prior to surgical resection. Promising pathologic response rates have been reported and the impact on survival is currently investigated in ongoing studies. ABSTRACT: In early-stage lung cancer, recurrences are observed even after curative resection. Neoadjuvant immunotherapy might be a promising approach to eliminate micrometastasis and to potentially reduce recurrence rates and improve survival. Early trials have shown encouraging rates of pathologic response to neoadjuvant therapy and have demonstrated that surgery can be safely performed after neoadjuvant immunotherapy with various agents and in combination with chemo-(radio)therapy. However, whether these response rates translate into improved disease-free survival rates and overall survival rates remains to be determined by ongoing phase III studies. MDPI 2021-08-10 /pmc/articles/PMC8393473/ /pubmed/34439187 http://dx.doi.org/10.3390/cancers13164033 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Stefani, Dirk Plönes, Till Viehof, Jan Darwiche, Kaid Stuschke, Martin Schuler, Martin Aigner, Clemens Lung Cancer Surgery after Neoadjuvant Immunotherapy |
title | Lung Cancer Surgery after Neoadjuvant Immunotherapy |
title_full | Lung Cancer Surgery after Neoadjuvant Immunotherapy |
title_fullStr | Lung Cancer Surgery after Neoadjuvant Immunotherapy |
title_full_unstemmed | Lung Cancer Surgery after Neoadjuvant Immunotherapy |
title_short | Lung Cancer Surgery after Neoadjuvant Immunotherapy |
title_sort | lung cancer surgery after neoadjuvant immunotherapy |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8393473/ https://www.ncbi.nlm.nih.gov/pubmed/34439187 http://dx.doi.org/10.3390/cancers13164033 |
work_keys_str_mv | AT stefanidirk lungcancersurgeryafterneoadjuvantimmunotherapy AT plonestill lungcancersurgeryafterneoadjuvantimmunotherapy AT viehofjan lungcancersurgeryafterneoadjuvantimmunotherapy AT darwichekaid lungcancersurgeryafterneoadjuvantimmunotherapy AT stuschkemartin lungcancersurgeryafterneoadjuvantimmunotherapy AT schulermartin lungcancersurgeryafterneoadjuvantimmunotherapy AT aignerclemens lungcancersurgeryafterneoadjuvantimmunotherapy |